Difference between revisions of "Venlafaxine-hypericum"
From Psychiatrienet
(Created page with '{{ Drugswitch | from = venlafaxine | to = hypericum | stop = * '''Before day 0:''' gradually reduce dosage of venlafaxine to a maximum of 75 mg/day, when this dosage is > 75 ...') |
|||
| Line 3: | Line 3: | ||
| to = hypericum | | to = hypericum | ||
| stop = | | stop = | ||
| − | + | {{downVenla}} | |
| − | |||
| − | |||
| start = | | start = | ||
| − | * '''Day | + | * '''Day 14-21:''' a wash-out period of one week is necessary. |
| − | * '''Day | + | * '''Day 22:''' start administration of hypericum. |
| info = | | info = | ||
| − | + | ||
| − | + | ||
| + | }} | ||
Revision as of 17:11, 17 July 2009
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from venlafaxine to hypericum.[1] [2]
Stop venlafaxine - Day 1-14: gradually reduce dosage of venlafaxine to a maximum of 37,5 mg or 75 mg (slow release)/ day.
- Day 15: stop administration of venlafaxine
Start hypericum- Day 14-21: a wash-out period of one week is necessary.
- Day 22: start administration of hypericum.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
